https://www.selleckchem.com/pr....oducts/PHA-793887.ht
An amendment to this paper has been published and can be accessed via the original article. Frailty is common in clinical practice, but trials rarely report on participant frailty. Consequently, clinicians and guideline-developers assume frailty is largely absent from trials and have questioned the relevance of trial findings to frail people. Therefore, we examined frailty in phase 3/4 industry-sponsored clinical trials of pharmacological interventions for three exemplar conditions type 2 diabetes mellitus (T2DM), rheumatoid arthriti
Like
Comment
Share
